Compare Stocks: IONS, ROIV, BNTX, and INSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$92.06 -3.3%	$99.04	$79.52 ▼ $124.00	$23.28B	1.25	872,380 shs	1.21 million shs
INSM Insmed	$100.48 -1.2%	$120.16	$90.39 ▼ $212.75	$22.22B	0.83	2.60 million shs	5.25 million shs
IONS Ionis Pharmaceuticals	$43.30 -1.9%	$53.07	$42.63 ▼ $86.74	$7.34B	0.38	4.25 million shs	3.35 million shs
ROIV Roivant Sciences	$34.21 -1.6%	$36.67	$15.90 ▼ $42.50	$25.10B	1.1	7.62 million shs	6.40 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-3.35%	-4.95%	-6.69%	+0.62%	-13.38%
INSM Insmed	-1.24%	-7.47%	-19.55%	-13.09%	-37.90%
IONS Ionis Pharmaceuticals	-1.95%	-1.59%	-23.65%	-25.67%	-38.11%
ROIV Roivant Sciences	-1.55%	-3.63%	-17.53%	-4.89%	+113.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$92.06 -3.3%	$99.04	$79.52 ▼ $124.00	$23.28B	1.25	872,380 shs	1.21 million shs
INSM Insmed	$100.48 -1.2%	$120.16	$90.39 ▼ $212.75	$22.22B	0.83	2.60 million shs	5.25 million shs
IONS Ionis Pharmaceuticals	$43.30 -1.9%	$53.07	$42.63 ▼ $86.74	$7.34B	0.38	4.25 million shs	3.35 million shs
ROIV Roivant Sciences	$34.21 -1.6%	$36.67	$15.90 ▼ $42.50	$25.10B	1.1	7.62 million shs	6.40 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-3.35%	-4.95%	-6.69%	+0.62%	-13.38%
INSM Insmed	-1.24%	-7.47%	-19.55%	-13.09%	-37.90%
IONS Ionis Pharmaceuticals	-1.95%	-1.59%	-23.65%	-25.67%	-38.11%
ROIV Roivant Sciences	-1.55%	-3.63%	-17.53%	-4.89%	+113.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.65	Moderate Buy	$125.69	36.53% Upside
INSM Insmed	2.96	Moderate Buy	$200.57	99.61% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$89.20	106.00% Upside
ROIV Roivant Sciences	2.85	Moderate Buy	$45.64	33.40% Upside

Current Analyst Ratings Breakdown

Latest IONS, ROIV, BNTX, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	INSM Insmed	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/8/2026	BNTX BioNTech	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold
10/7/2026	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$115.00 ➝ $114.00
10/6/2026	INSM Insmed	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
10/2/2026	BNTX BioNTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/30/2026	INSM Insmed	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$237.00 ➝ $207.00
9/24/2026	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/24/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$85.00
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/24/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.65B	8.79	$1.29 per share	71.34	$96.59 per share	0.95
INSM Insmed	$606.42M	36.18	N/A	N/A	$3.46 per share	29.04
IONS Ionis Pharmaceuticals	$944M	7.62	N/A	N/A	$3.02 per share	14.34
ROIV Roivant Sciences	$8.26M	2,991.59	N/A	N/A	$7.35 per share	4.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	104.67	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest IONS, ROIV, BNTX, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.21	N/A	N/A	N/A	$183.13 million	N/A
11/3/2026	Q3 2026	BNTX BioNTech	$0.8380	N/A	N/A	N/A	$1.20 billion	N/A
10/29/2026	Q3 2026	INSM Insmed	-$0.3981	N/A	N/A	N/A	$499.31 million	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
INSM Insmed	0.74	3.72	3.40
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
INSM Insmed	N/A
IONS Ionis Pharmaceuticals	93.86%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
INSM Insmed	2.10%
IONS Ionis Pharmaceuticals	1.81%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

IONS, ROIV, BNTX, and INSM Headlines

Recent News About These Companies

Fig Financial Advisory Services Inc. ADV Buys New Position in Roivant Sciences Ltd. $ROIV

October 8 at 3:20 AM | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Has Consensus Target Price of $45.64

October 7 at 4:15 AM | americanbankingnews.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

October 7 at 4:13 AM | marketbeat.com

Comparing Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)

October 6 at 6:15 AM | americanbankingnews.com

Roivant Sciences (NASDAQ:ROIV) Director Sells 17,750 Shares of Company Stock

October 6 at 4:22 AM | insidertrades.com

Roivant Sciences (NASDAQ:ROIV) Stock: Insider Melissa Epperly Sells 17,750 Shares

October 5, 2026 | marketbeat.com

Roivant's Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV)

October 5, 2026 | americanbankingnews.com

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

October 5, 2026 | biospace.comB

Roivant’s Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV)

October 4, 2026 | defenseworld.netD

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Company Stock

October 3, 2026 | americanbankingnews.com

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

October 3, 2026 | insidertrades.com

Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares of Company Stock

October 2, 2026 | marketbeat.com

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

September 28, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

September 27, 2026 | theglobeandmail.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

September 27, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)

September 24, 2026 | theglobeandmail.com

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

September 24, 2026 | finance.yahoo.com

Roivant's Immunovant Unit to Stop IMVT-1402 Development in Cutaneous Lupus Erythematosus

September 23, 2026 | finance.yahoo.com

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026 | globenewswire.com

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026 | globenewswire.com

Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12:20 PM

September 22, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IONS, ROIV, BNTX, and INSM Company Descriptions

BioNTech NASDAQ:BNTX

$92.06 -3.19 (-3.35%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$92.42 +0.36 (+0.39%)

As of 09:18 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Insmed NASDAQ:INSM

$100.48 -1.26 (-1.24%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$100.00 -0.48 (-0.48%)

As of 09:18 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Ionis Pharmaceuticals NASDAQ:IONS

$43.30 -0.86 (-1.95%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$43.57 +0.27 (+0.61%)

As of 09:20 AM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Roivant Sciences NASDAQ:ROIV

$34.21 -0.54 (-1.55%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$34.38 +0.16 (+0.48%)

As of 09:22 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ROIV, BNTX, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ROIV, BNTX, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ROIV, BNTX, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ROIV, BNTX, and INSM Company Descriptions

BioNTech NASDAQ:BNTX

Insmed NASDAQ:INSM

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ROIV, BNTX, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ROIV, BNTX, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ROIV, BNTX, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ROIV, BNTX, and INSM Company Descriptions

BioNTech NASDAQ:BNTX

Insmed NASDAQ:INSM

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools